Novotech Report Reveals Growth in siRNA Research: Over 150 Industry-Sponsored Clinical Trials Conducted from 2020 to 2024
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of small interfering RNA (siRNA) therapeutics. This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to develop next-generation treatments for oncology, metabolic disorders, and rare genetic diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327730371/en/
Unlocking the Potential of siRNA for Drug Development
siRNA therapeutics represent a paradigm shift in targeted drug development by enabling precise gene silencing of disease-causing genes. With the FDA approval of multiple siRNA-based drugs, including ONPATTRO™ (Patisiran) and Inclisiran, the field is witnessing rapid advancements in delivery platforms, stability, and tissue-specific targeting. Novotech’s report outlines the current research and regulatory landscape, highlighting how siRNA technologies are expanding the druggable genome, addressing previously undruggable targets.
Key highlights
- Clinical and Regulatory Landscape: Overview of the six FDA-approved siRNA therapies and their expanding indications in cardiovascular, hepatic, and rare genetic diseases.
- Advancements in siRNA Delivery: Innovations in lipid nanoparticles (LNPs), GalNAc conjugates, and polymeric nanoparticles enhancing targeted tissue delivery and minimizing immune-related challenges
- Expanding Applications in Oncology: siRNA’s role in silencing oncogenes, overcoming drug resistance, and targeting tumor microenvironments, positioning it as a promising alternative to traditional cancer treatments.
- Clinical Trial Growth & Future Outlook: Analysis of the 150+ industry-sponsored siRNA clinical trials conducted between 2020 and 2024, with a 79.5% CAGR reflecting significant industry investment.
Partnering for Success in siRNA Clinical Development
As a leading global provider of end-to-end clinical trial services, Novotech partners with biotech and pharmaceutical innovators to accelerate the development of siRNA therapeutics. With expertise in RNA research and over 25 years of experience in clinical trial execution, Novotech provides the comprehensive regulatory guidance, strategic site selection, and expert trial management to navigate the complexities of siRNA drug development-ensuring efficiency, compliance and success at every phase.
About NovotechNovotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations. Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327730371/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Decent Cybersecurity to Showcase Post-Quantum Solutions at DSEI Japan 202516.5.2025 09:49:00 CEST | Press release
Decent Cybersecurity announces its participation at DSEI Japan 2025 as the only Slovak cybersecurity company exhibiting at this premier defense event in Makuhari Messe, Chiba (May 21-23, 2025). The company will showcase its advanced post-quantum security solutions for aerospace, defense, and space sectors, including SpaceShield STM, DroneCrypt UTM, and QuantumProof Protocol. "The Indo-Pacific region represents a critical frontier for post-quantum cybersecurity innovation as quantum computing advances threaten traditional encryption," said Matej Michalko, Founder, Chairman and CEO of Decent Cybersecurity. "Our participation demonstrates our commitment to offering Japanese defense and space agencies access to European-certified, quantum-resistant security solutions that protect critical infrastructure against emerging threats." As a holder of NATO, EU, and national security clearances at the "Secret" level, Decent Cybersecurity brings unique post-quantum security credentials to the Japan
LTIMindtree, Eurobank and Fairfax Digital Services Collaborate to Build Digital Innovation Hub in Cyprus16.5.2025 09:00:00 CEST | Press release
This center will facilitate the development of Advanced Digital Solutions for Eurobank, Fairfax and other EU customers. LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the opening of its Digital Innovation Hub at the Research and Innovation Hub of CYENS Center of Excellence. The LTIMindtree Digital Innovation Hub will enable ideation, co-creation and implementation of Advanced Digital Solutions for Eurobank, Fairfax and other EU customers and aligns with the strategic vision of the Cyprus Government to strengthen Cyprus’ role as a regional tech and innovation hub, triggering unique cross-border opportunities for tech collaborations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515054331/en/ Srini Rao EVP & Chief Business Officer- Europe, LTIMindtree | Mr. Nikodemos Damianou, Deputy Minister of Research and Innovation, Govt of Cyprus | Mr. Fokion Karavias,
ROYC Acts as the Structuring and Financial Technology Partner for Riverside for European Wealth Access Fund16.5.2025 08:30:00 CEST | Press release
ROYC, the leading provider of complete private markets operating systems, announces the structuring of a new access fund for Private Wealth launched in collaboration with The Riverside Company. The Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 1,000 investments and today has over $12 billion in assets under management. The firm's international private equity and structured capital portfolios include more than 140 companies. The Riverside’s proven investment strategy of acquiring and developing high-potential European SMEs in resilient, growth-oriented sectors, including technology and software, healthcare, advanced manufacturing and consumer products. “This fund represents a unique opportunity for wealth investors to access value creation generally reserved for institutional investors,” says Karsten Langer, Managing Partner at Riverside Europe and contin
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 22:51:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 20:30:00 CEST | Press release
Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapyPatients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Thi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom